{"id":"cholecalciferol-100-000-ui-administration","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypercalcemia"},{"rate":null,"effect":"Hyperphosphatemia"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Vomiting"},{"rate":null,"effect":"Constipation"}]},"_chembl":{"chemblId":"CHEMBL1042","moleculeType":"Small molecule","molecularWeight":"384.65"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Cholecalciferol is a fat-soluble vitamin that undergoes hydroxylation in the liver and kidneys to form the active hormone calcitriol (1,25-dihydroxyvitamin D3). The active metabolite binds to vitamin D receptors in target tissues, promoting intestinal calcium and phosphate absorption, regulating bone mineralization, and modulating immune cell differentiation and function. This mechanism makes it therapeutically relevant for conditions involving mineral metabolism disorders and potentially immune-mediated diseases.","oneSentence":"Cholecalciferol (vitamin D3) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:44:56.489Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Vitamin D deficiency in chronic kidney disease patients"},{"name":"Secondary hyperparathyroidism management"},{"name":"Mineral bone disorder in renal disease"}]},"trialDetails":[{"nctId":"NCT01817166","phase":"PHASE3","title":"Efficacy of Cholecalciferol (Vitamin D3) for Delaying the Diagnosis of MS After a Clinically Isolated Syndrome","status":"COMPLETED","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2013-07-16","conditions":"Multiple Sclerosis","enrollment":316},{"nctId":"NCT04262934","phase":"PHASE3","title":"Does Correction of 25 OH-VITAmin D With Cholecalciferol Supplementation Increase Muscle Strength in hemoDIALysis Patients?","status":"UNKNOWN","sponsor":"Institut Phoceen de Nephrologie","startDate":"2018-01-08","conditions":"hemoDIALysis Patients","enrollment":150}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Cholecalciferol 100.000 UI administration","genericName":"Cholecalciferol 100.000 UI administration","companyName":"Institut Phoceen de Nephrologie","companyId":"institut-phoceen-de-nephrologie","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Cholecalciferol (vitamin D3) is converted in the body to its active form, calcitriol, which regulates calcium and phosphate homeostasis and modulates immune function. Used for Vitamin D deficiency in chronic kidney disease patients, Secondary hyperparathyroidism management, Mineral bone disorder in renal disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}